Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer

Puyuan Xing*, Yuxin Mu*, Yan Wang, Xuezhi Hao, Yixiang Zhu ©, Xingsheng Hu, Hongyu Wang, Peng Liu, Lin Lin, Zhijie Wang & Junling Li

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Keywords
Bevacizumab; chemotherapy; non-small cell lung cancer; progression-free survival; safety.

Abstract

Background: Large scale randomized controlled trials have demonstrated that the use of bevacizumab in addition to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) conveys significant survival benefits. We explored the clinical impact of a first-line regimen containing bevacizumab (B+) versus a non-bevacizumab regimen (non-B) in advanced non-squamous NSCLC (NS-NSCLC) patients in a real world setting.

Methods: The medical records of patients with advanced NS-NSCLC who received first-line therapy with or without bevacizumab were retrospectively collected. The primary outcome was progression-free survival (PFS), with secondary objectives of objective response rate (ORR), disease control rate (DCR), and safety. Exploratory analysis of EGFR and ALK status was conducted in subgroup.

Results: One hundred and forty-nine patients met the selection criteria: 62 in the B+ and 87 in the non-B group. The baseline characteristics were well balanced. In the overall population, the median PFS was significantly longer in the B+ than in the non-B group (9.7 vs. 7.0 months, hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.30–0.91; P = 0.0184). Improved trends in both ORR and DCR were observed in the B+ group. In wild-type patients, the median PFS of the B+ was 11.3 compared to 5.5 months in the non-B group (HR 0.43, 95% CI 0.20–0.91; P = 0.0234). In wild type and unknown populations, the median PFS was 11.3 (B+) compared to 6.0 months (non-B) (HR 0.53; 95% CI 0.28–1.02; P = 0.0520). The safety profile was acceptable in both groups and no unexpected findings were observed.

Conclusion: Our analysis confirmed that a first-line regimen containing bevacizumab showed superior clinical benefits over a non-bevacizumab regimen in Chinese patients with advanced NS-NSCLC in a real world setting.

Introduction

Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancer diagnoses and most patients present with advanced stage at the time of diagnosis. Current standard first-line treatment for advanced NSCLC is platinum-based doublet chemotherapy when no targetable alterations, such as EGFR mutations or ALK or ROS1 rearrangements, are detected in genomic testing. However, the response rate of chemotherapy regimens is only 15–30%, with high toxicity, and the prognosis for these patients is extremely poor, with five-year survival rates reported at < 5%. Additional therapeutic options are urgently required. Bevacizumab, a recombinant humanized monoclonal antibody that binds VEGF-A and prevents interaction with VEGFR-1 and VEGFR-2 (the primary receptors involved in endothelial cell proliferation and migration), reduces tumor expansion by controlling abnormal growth of blood vessels around the...
tumor. Several pivotal trials have proven the efficacy of bevacizumab in patients with advanced NSCLC as first-line treatment in combination with platinum-based chemotherapy. An Eastern Cooperative Oncology Group (ECOG) randomized controlled trial (E4599) demonstrated that patients treated with bevacizumab–carboplatin–paclitaxel (BCP) had significantly longer median overall survival (OS) than those treated with carboplatin–paclitaxel (CP) alone (12.3 vs. 10.3 months, hazard ratio [HR] 0.79; \( P = 0.003 \)). Similar efficacy was also observed in other pivotal studies, extending OS and progression-free survival (PFS). These studies included mainly Caucasian patients. Subsequent subgroup analyses in the Avastin in Lung (AVAiL) and phase IV Safety of Avastin in Lung (SAiL) studies suggested that bevacizumab is also efficacious in Asian populations. The randomized, double-blind, multicenter, placebo-controlled, phase III BEYOND trial confirmed higher PFS, OS, and overall response rate (ORR) in the BCP compared to the CP group in a Chinese population. However, these clinical trials were designed for highly selected patients and standardized conditions different from the realities of real-world clinical practice settings. Patients with brain metastases and poor ECOG performance status (PS > 1) were virtually excluded because of the risk of hemorrhage, which inhibits the widespread use of bevacizumab, as approximately 25–30% of patients with NSCLC will ultimately be diagnosed with brain metastases, and this is also often the first site of recurrence in patients initially treated for early-stage disease. Thus, there is a lack of real world evidence to illustrate the effectiveness and safety of bevacizumab. Therefore, we retrospectively assessed the real-world outcomes of patients with advanced non-squamous NSCLC who received first line regimens with or without bevacizumab at our Cancer Center.

**Assessment**

The primary outcome was progression-free survival (PFS), with secondary objectives of ORR, disease control rate (DCR), and treatment-induced toxicities in patients with NS-NSCLC. Exploratory analysis of EGFR and ALK status was conducted in subgroup.

Disease response to treatment was assessed according to Response Evaluation Criteria in Solid Tumors. PFS was defined as the duration from the start of treatment until disease progression or death from any cause. DCR was defined as complete response (CR), partial response (PR), or stable disease (SD) ≥ 6 weeks, while ORR was defined as CR or PR. In subgroup analysis, the wild-type subgroup refers to EGFR negative/ALK negative, EGFR negative/ALK unknown, and EGFR unknown/ALK negative populations. Wild type and unknown subgroups were defined as EGFR negative/ALK negative, EGFR negative/ALK unknown, EGFR unknown/ALK negative, and EGFR unknown/ALK unknown populations. Adverse events (AEs) were recorded according to Common Terminology Criteria for Adverse Events version 4.0. Other baseline clinical variables included age, gender, ECOG PS, smoking history, histology, disease stage, EGFR status, ALK status, brain metastasis, and concomitant chemotherapy.

**Statistics analysis**

The distribution of patients’ baseline demographic/clinical characteristics (age, gender, ECOG status, smoking status, histology, disease stage, EGFR/ALK status, brain metastasis) and treatment patterns were described using frequency analysis. Chi-square and Fisher’s exact tests were used for categorical variables and a t-test for continuous variables to assess the difference between the two treatment groups at baseline. The Kaplan–Meier method was applied to obtain the distribution function for PFS. A log-rank test was used to evaluate the difference between the two groups. Cox regression was used to explore the potential predictors for PFS and results from both univariate and multivariate models are reported. ORR and DCR were compared using chi-square or Fisher’s exact tests. All analysis was performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and alpha = 0.05 was used as a significance level in all statistical testing.

**Results**

**Patients and characteristics**

From July 2009 to December 2016, 149 patients with advanced NS-NSCLC administered first-line therapy with or without bevacizumab at our hospital were retrospectively reviewed. All 149 patients met the selection criteria:

**Methods**

**Data source and study population**

The medical data of patients who visited the Cancer Hospital, Chinese Academy of Medical Sciences from July 2009 to December 2016 were collected. Eligible patients were required to be newly diagnosed with stage IIIB or IV cancer based on the American Joint Committee on Cancer 7th Edition Cancer Staging Manual with histologically or cytologically confirmed NS-NSCLC. Study subjects were classified into two mutually exclusive groups according to their first-line regimen: bevacizumab-containing (B+) and non-bevacizumab (non-B). A total of 149 patients were included in this study.
62 in the B+ and 87 in the non-B group. Chemotherapy was the standard treatment in both groups: 57 patients in the B+ and 71 in the non-B group. All other patients were treated with EGFR/ALK tyrosine kinase inhibitors (TKIs). Most of the patients administered concomitant chemotherapy were treated with doublet-chemotherapy (55/62 and 66/87 in B+ and non-B groups, respectively). An evaluation of efficacy was possible in 60 and 77 patients in the B+ and non-B groups, respectively. Baseline characteristics of study population are shown in Table 1, including age, gender, ECOG status, smoking status, histology, disease stage, EGFR/ALK status, and brain metastasis.

**Clinical outcomes**

The median follow-up duration was 10.7 months. In the overall population, the median PFS was significantly longer in the B+ than in the non-B group: 9.7 versus 7.0 months ($P = 0.0184$) (Fig 1). Although the differences in ORR and DCR were not statistically significant, both measurements were higher in the B+ group (63.33% vs. 51.95% for ORR, $P = 0.1818$; and 93.33% vs. 85.71% for DCR, $P = 0.1565$). Similar trends were observed in all subgroup analyses. In the wild-type subgroup, the median PFS in the B+ group was 11.3 compared to 5.5 months in the non-B group ($P = 0.0234$) (Fig 2). ORR and DCR in the B+ and non-B groups were 55.17% vs. 38.24% ($P = 0.1788$) and 96.55% vs. 79.41% ($P = 0.0598$), respectively. The median PFS in the population with wild type and unknown EGFR/ALK status was 11.3 (B+) compared to 6.0 months (non-B) ($P = 0.0520$) (Fig 3). The ORR and DCR in the two groups were 56.10% vs. 46.30% ($P = 0.3440$) and 92.68% vs. 83.33% ($P = 0.1743$), respectively.

Table 1  Baseline characteristics of NS-NSCLC patients at first-line therapy ($n = 149$)

| Characteristics                           | All ($n = 149$) | B+ ($n = 62$) | Non-B ($n = 87$) | $P$  |
|-------------------------------------------|-----------------|--------------|-----------------|------|
| Age, years                                |                 |              |                 |      |
| Median                                    | 53.0            | 54.0         | 53.0            | 0.2885|
| Mean                                      | 53.1            | 54.2         | 52.4            |      |
| Range                                     | 25–75           | 30–73        | 25–75           |      |
| Gender                                    |                 |              |                 | 0.9924|
| Male                                      | 101 (67.8)      | 42 (67.7)    | 59 (67.8)       |      |
| Female                                    | 48 (32.2)       | 20 (32.3)    | 28 (32.2)       |      |
| ECOG PS†                                   |                 |              |                 | 0.5282|
| 0                                         | 45 (30.41)      | 22 (35.48)   | 23 (26.74)      |      |
| 1                                         | 100 (67.57)     | 39 (62.90)   | 61 (70.93)      |      |
| 2                                         | 3 (2.03)        | 1 (1.61)     | 2 (2.33)        |      |
| Smoking status‡                           |                 |              |                 | 0.2402|
| Non-smoker                                | 65 (45.1)       | 31 (50.8)    | 34 (41.0)       |      |
| Former/current smoker                     | 79 (54.9)       | 30 (49.2)    | 49 (59.0)       |      |
| Histology                                 |                 |              |                 | 0.4928|
| Adenocarcinoma                            | 134 (89.9)      | 57 (91.9)    | 77 (88.5)       |      |
| Others                                    | 15 (10.1)       | 5 (8.1)      | 10 (11.5)       |      |
| Disease stage                             |                 |              |                 | 0.1476|
| IIIB                                      | 19 (12.8)       | 5 (8.1)      | 14 (16.15)      |      |
| IV                                        | 130 (89.3)      | 57 (91.9)    | 73 (83.9)       |      |
| Driver mutation test§                     |                 |              |                 | 0.7775|
| EGFR positive                             | 35              | 16           | 19              |      |
| ALK positive                              | 14              | 4            | 10              | 0.1886|
| Brain metastasis                          | 22              | 8            | 14              | 0.5886|
| Concomitant chemotherapy                  |                 |              |                 | 0.1693|
| Non                                       | 21 (14.09)      | 5 (8.06)     | 16 (18.39)      |      |
| Mono-chemotherapy                         | 7 (4.70)        | 2 (3.23)     | 5 (5.75)        |      |
| Pemetrexed-based                          | 2               | 1            | 1               |      |
| Paclitaxel-based                          | 0               | 0            | 0               |      |
| Doublet-chemotherapy                      | 121 (81.21)     | 55 (88.71)   | 66 (75.86)      |      |
| Pemetrexed-based                          | 88              | 46           | 42              |      |
| Paclitaxel-based                          | 9               | 3            | 6               |      |

†Data of one patient was missing. ‡Data of five patients were missing. §Both EGFR and ALK positive: 2. ECOG PS, Eastern Cooperative Oncology Group performance status; NS-NSCLC, non-squamous non-small cell lung cancer.
In patients with brain metastases, progression was observed in two patients (2/8, 25.00%) in the B+ and 11 (11/14, 78.57%) in the non-B group. ORR and DCR were 50.00% and 100.00% in the B+ compared to 76.92% and 92.31% in the non-B group. In patients with an ECOG PS of 1–2, the median PFS in B+ was 9.7 months, which was significantly longer than in the non-B group at 6.0 months ($P = 0.0023$) (Fig 4). There were similar trends
in ORR and DCR (57.98% vs. 53.70% for ORR, \( P = 0.6905 \); and 92.11% vs. 81.48% for DCR, \( P = 0.1498 \)). Overall survival (OS) was not reached.

The results of Cox regression are reported in Table 2. In the univariate model, first-line bevacizumab use was associated with better PFS (HR 0.52; \( P = 0.0205 \)) and this association remained stable after adjusting for gender, age, \( EGFR \)/ALK status, smoking status, and concomitant pemetrexed use (HR 0.48; \( P = 0.0217 \)). Tables 3 and 4 show the results of treatment response and survival analysis.

### Safety

Safety analysis was conducted in the whole population. The most common AEs were myelosuppression and gastrointestinal disorders in both groups. Grade 3/4 AEs were acceptable, with 16/62 (25.8%) in the B+ and 23/87 (26.4%) in the non-B group, including leukopenia, neutropenia, thrombocytopenia, anemia, anorexia, and increased gamma-glutamyl transferase. No AEs appeared to increase after bevacizumab administration. Specific AEs in the B+ group included bleeding with epistaxis (2/62, 3.2%) and hypertension (1/62, 1.6%). No drug-related deaths or unexpected safety issues were observed in the study. Table 5 shows the AEs in both groups.

### Discussion

The primary end point of this study was to assess the efficacy of first-line bevacizumab in a real world population of patients with NS-NSCLC. The study findings confirm the efficacy of bevacizumab with a manageable safety profile, support the use of bevacizumab in first-line treatment, and establish the relevance of findings of randomized phase III (E4599, AVAiL)\(^6,7\) and phase IV (SAiL and Aries)\(^8,13\) studies.

We explored the clinical impact of first-line therapy with (B+) or without (non-B) bevacizumab for patients with advanced NS-NSCLC in a real world setting. The baseline characteristics were well balanced, including patients with brain metastasis and ECOG PS > 1. In the overall population, the median PFS was significantly longer in the B+ than in the non-B group (9.7 vs. 7.0 months, HR 0.52, 95% CI 0.30–0.91; \( P = 0.0184 \)). The PFS in our study (9.7 months) was comparable to findings observed in previous Asian subpopulation analyses, including the BEYOND trial\(^9\) (9.2 months), the AVAiL East Asian sub-group\(^7\) (8.2 months), and the SAiL East Asian population,\(^14\) which reported a median time to progression of 8.3 months, with further subgroup analysis of Chinese patients demonstrating a median time to progression of 8.8 months.\(^8\) In multivariate analysis, there was no distinction in PFS when stratified by gender, age, smoking history, or \( EGFR \)/ALK gene status. Improved trends in both ORR and DCR were observed in the B+ group, with ORRs of 63.33% vs. 51.95% (\( P = 0.1818 \)) and DCRs of 93.33% vs. 85.71% (\( P = 0.1565 \)), respectively. The higher ORR and DCR in both groups in our study may have occurred because 8.06% and 18.39% of B+ and non-B group

---

**Table 2** Cox regression for PFS

| Characteristics              | Crude HR | Crude P  | Adjusted HR | Adjusted P |
|------------------------------|----------|----------|-------------|------------|
| Male                         | 0.83     | 0.4231   | 0.53        | 0.0563     |
| Age group (≤ 65)             | 0.77     | 0.5251   | 0.57        | 0.2039     |
| Wild type                    | 1.29     | 0.285    | 1.33        | 0.1946     |
| First-line bevacizumab use   | 0.52     | 0.0205   | 0.48        | 0.0217     |
| Smoker                       | 1.24     | 0.3116   | 1.55        | 0.1423     |
| Pemetrexed use               | 1.31     | 0.1937   | 1.38        | 0.1629     |

HR, hazard ratio; PFS, progression-free survival.
Bevacizumab as first-line for NSCLC

P. Xing et al.

Table 3 ORR and DCR in overall population, wild-type patients, wild-type and unknown patients, patients with brain metastasis and patients with ECOG PS 1–2

| Type of patients | Index | B+ (n = 62) | non-B (n = 87) | P* |
|------------------|-------|------------|---------------|----|
| Overall population | ORR | 38/60 (63.33) | 40/77 (51.95) | 0.1818 |
|                   | DCR  | 56/60 (93.33) | 66/77 (85.71) | 0.1565 |
| Wild-type patients | ORR | 16/29 (55.17) | 13/34 (38.24) | 0.1788 |
|                   | DCR  | 28/29 (96.55) | 27/34 (79.41) | 0.0598** |
| Wild type and unknown patients | ORR | 23/41 (56.10) | 25/54 (46.30) | 0.3440 |
|                   | DCR  | 38/41 (92.68) | 45/54 (83.33) | 0.1743 |
| Brain metastasis | ORR | 4/8 (50.00) | 10/13 (76.92) | 0.3458 |
|                   | DCR  | 8/8 (100.00) | 12/13 (92.31) | 1.0000 |
| ECOG PS 1–2 | ORR | 22/38 (57.89) | 29/54 (53.70) | 0.6905 |
|                   | DCR  | 35/38 (92.11) | 44/54 (81.48) | 0.1498 |

*Chi-square test used, unless specified. **Fisher’s exact test. DCR, disease control rate; ECOG PS, Eastern Cooperative Oncology Group performance status; ORR, overall response rate; PFS, progression-free survival.

Table 4 PFS in different types of patients

| Types of patients | Treatments | Median PFS (months) | Log-rank P |
|------------------|------------|---------------------|------------|
| Overall patients | B+         | 9.7                 | 0.0184     |
|                  | Non-B      | 7.0                 |            |
| Wild type patients | B+     | 11.3                | 0.0234     |
|                  | Non-B      | 5.5                 |            |
| Wild type and unknown patients | B+   | 11.3                | 0.0520     |
|                  | Non-B      | 6.0                 |            |
| ECOG PS 1–2 | B+         | 9.7                 | 0.0023     |
|                  | Non-B      | 6.0                 |            |

ECOG PS, Eastern Cooperative Oncology Group performance status; PFS, progression-free survival.

patients, respectively, harboring activating mutations in EGFR/ALK had been treated with EGFR/ALK-TKIs. Several studies have demonstrated a survival benefit in patients with EGFR exon19del mutations treated with bevacizumab plus gefitinib or erlotinib.15,16

Currently, targeted therapies, such as EGFR and ALK TKIs, are being developed to improve efficacy in selected patients with advanced NSCLC; thus patients with EGFR/ALK gene mutations are usually administered corresponding targeted therapy as first-line treatment. However, patients without EGFR/ALK mutations and those with inadequate samples for gene testing may be excluded from EGFR/ALK-TKI therapy, and previous studies have shown no benefit of using bevacizumab plus TKIs in EGFR-unselected patients.17–19 For these patients, chemotherapy is still the primary choice, therefore it is important to find an effective and safe regimen for this population. Thus, we explored the efficacy and safety of bevacizumab use in wild type, and in wild type and unknown populations excluded from targeted therapy. In wild-type patients, the median PFS of the B+ was 11.3 compared to 5.5 months in the non-B group (HR 0.43, 95% CI 0.28–0.91; P = 0.0234). In the wild type and unknown population, the median PFS was 11.3 (B+) compared to 6.0 months (non-B) (HR, 0.53; 95% CI, 0.28–1.02; P = 0.0520), with a higher ORR and DCR in the B+ group. The results of our subgroup analysis are consistent with results of the BEYOND trial (8.3 vs. 5.6 months of B+ CP and Pl+ CP groups in EGFR wild-type tumors), which identified that therapy containing bevacizumab may present a better choice in patients with EGFR/ALK gene negative or unknown status.9

In addition, previous studies have shown that penetration of cytotoxic agents and humanized monoclonal antibodies to the blood brain barrier is low,20,21 thus data of efficacy of bevacizumab in patients with brain metastases (BM) is lacking. Our study demonstrated a higher DCR in the B+ group of patients with BM than in the non-B group. The median PFS of BM patients in the B+ group was not reached, and progression was only observed in two patients, which suggests acceptable efficacy of bevacizumab in NSCLC patients with BM. However, further studies including BM patients are needed. In regard to AEs and tolerability, bevacizumab was used with caution in patients with ECOG PS ≥1. A significantly longer median PFS in patients with ECOG PS 1–2 was observed in the B+ group, which suggests bevacizumab has a tolerable safety profile.
Although pemetrexed plus platinum is the traditional standard regimen for first-line treatment of NS-NSCLC, the concomitant chemotherapy regimens used in previous studies were mainly carboplatin/cisplatin plus paclitaxel, or gemcitabine plus cisplatin. Several studies have explored the efficacy of pemetrexed-based chemotherapy plus bevacizumab. The PointBreak study was the first to compare pemetrexed/carboplatin plus bevacizumab with paclitaxel/carboplatin plus bevacizumab in patients with advanced NSCLC, and demonstrated a significant difference in PFS between the two arms (6.0 vs. 5.6 months, respectively), but not in OS. In our study, most patients received pemetrexed-based therapy, which reflects real world clinical practice. The improved PFS, ORR, and DCR may be attributed to the use of pemetrexed, but further clinical trials and real world data are required to confirm our results.

The safety profile was acceptable in both groups. The percentage of ≥ grade 3 AEs was 16/62 in the B+ and 23/87 in the non-B groups, illustrating that a regimen containing bevacizumab may not cause further AEs. No unexpected findings were observed. In general, the addition of bevacizumab was well tolerated. Bevacizumab did not increase the incidence of myelosuppression, diarrhea, nausea, vomiting, mucositis, or liver dysfunction relative to chemotherapy or TKI alone. Epistaxis and hypertension have been observed in other clinical trials of bevacizumab. These events were also observed in this study, but were minor in severity and did not require discontinuation of bevacizumab. Other mechanism-based AEs observed in clinical trials, including proteinuria, gastrointestinal perforation, and thromboembolic events, were not observed in this study, which may be attributed to good performance status (ECOG PS ≤ 1 accounted for 98.4% and 97.7% in the B+ and non-B groups, respectively).

There are a number of advantages of our study. The data used is relatively new, which may reflect current medical practice. We also included elderly patients, and patients with ECOG PS > 1 and BM, which are usually excluded from prospective clinical trials. Nevertheless, our study has several limitations, including its single-center, retrospective design. The higher PFS observed in the B+ group may have resulted from the selection of patients without cardiovascular disease, or less cerebral metastasis. Our sample of patients with ECOG PS 2 was small, and may have influenced our results regarding the tolerability of chemotherapy and bevacizumab.

Based on this retrospective analysis, a regimen containing bevacizumab is an effective first-line strategy for patients with advanced NS-NSCLC, yielding improved PFS, ORR and DCR, particularly in driver gene negative or unknown patients, with tolerable and manageable AEs.

**Acknowledgments**

The authors would like to thank Yi Wen, an employee of Medbanks Network Technology Co. Ltd., for guidance with statistical analysis. We are grateful to all patients and their family members.

**Disclosure**

No authors report any conflict of interest.
References

1. Zhu QG, Zhang SM, Ding XX, He B, Zhang HQ. Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget 2017; 8: 57680–92.

2. Sun J, Hu Y, Wu BS, Wang JL, Tao HT, Zhang SJ. Bevacizumab concomitant with chemotherapy is effective in treating Chinese patients with advanced non-squamous non-small cell lung cancer. Asian Pac J Cancer Prev 2014; 15: 5945–50.

3. Malhotra, J, Jabbour, S.K., Aisner, J. Current state of immunotherapy for non-small cell lung cancer. (Published erratum appears in Transl Lung Cancer Res 6 (2), 196–211 (2017).

4. Tabchi, S, Blais N. Antiangiogenesis for advanced non-small-cell lung cancer in the era of immunotherapy and personalized medicine. Front Oncol 2017; 7: 52.

5. Silva AP, Coelho PV, Anazetti M, Simioni PU. Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. Hum Vaccin Immunother 2017; 13: 843–53.

6. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50 (Published erratum appears in N Engl J Med 2007;356:318).

7. Mok TS, Hsia TC, Tsai CM et al. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial. Asia Pac J Clin Oncol 2011; 7(Suppl 2): 4–12 (Published erratum appears in Asia Pac J Clin Oncol 2011; 7: 321).

8. Zhou CC, Bai CX, Guan ZZ et al. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: Data of subgroup analyses from MO19390 (SAiL) study. Clin Transl Oncol 2014; 16: 463–8.

9. Zhou C, Wu YL, Chen G et al. BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 2015; 33: 2197–204.

10. Langer C, Ravelo A, Hazard SJ et al. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: A retrospective cohort study. Lung Cancer 2014; 86 (3): 350–7.

11. Lunacek OE, Ravelo A, Coutinho AD et al. First-line treatment with bevacizumab and platinum doublet combination in non-squamous non-small cell lung cancer: A retrospective cohort study in US oncology community practices. Drugs Real World Outcomes 2016; 3: 333–43.

12. Scettino C, A. Bareshimo, M, Rossi A et al. Targeting angiogenesis for treatment of NSCLC brain metastases. Curr Cancer Drug Targets 2012; 12: 289–99.

13. Lynch TJ Jr, Spigel DR, Brahmer J et al. Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: Final results of the ARIES observational cohort study. J Thorac Oncol 2014; 9: 1332–9.

14. Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: Results from the phase IV MO19390 (SAIL) study. J Thorac Oncol 2011; 6: 1092–7.

15. Seto T, Kato T, Nishio M et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15: 1236–44 (Published erratum appears in Lancet Oncol 2014;15:e475.).

16. Ichihara E, Hotta K, Nogami N et al. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: The Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol 2015; 10: 486–91.

17. Thomas M, Fischer J, Andreas S et al. Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer. Eur Respir J 2015; 46: 219–29.

18. Ciuleanu T, Tsai CM, Tsao CJ et al. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer. Lung Cancer 2013; 82: 276–81.

19. Cohen, EE, Subramanian, J, Gao, F et al. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): Erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer 2012; 13: 123–8.

20. Zimmermann S, Dziadziszko R, Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev 2014; 40: 716–22.

21. Wilhelm I, Molnár J, Fazakas C, Haskó J, Krizbai IA. Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci 2013; 14: 1383–411.

22. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543–51.

23. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 2009; 14: 253–63.

24. Nuijt M, Heigener DF, Bischoff HG et al. Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2010; 69(Suppl 1): 54–10 (Published
errata appear in *Lung Cancer* 2010; 70:230 and *Lung Cancer* 2010; 69 (Suppl 1):S131.

25 Galetta D, Cinieri S, Pisconti S et al. Cisplatin/pemetrexed followed by maintenance pemetrexed versus carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE phase III randomized trial. *Clin Lung Cancer* 2015; 16: 262–73.

26 Chang GC, Ahn MJ, Wright E et al. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. *Asia Pac J Clin Oncol* 2011; 7 (Suppl 2): 34–40.

27 Patel JD, Socinski MA, Garon EB et al. PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. *J Clin Oncol* 2013; 31: 4349–57.